来源：瑞恩资本RyanbenCapital 中国企业赴香港上市，需要取得中国证监会的备案通知书。根据港交所上市规则，中国企业需在上市聆 讯审批日期至少4个营业日之前提交"备案通知书"。只有通过港交所的上市聆讯，企业才可以在港交所 挂牌上市。 本周(2025年11月17日至11月21日)中国证监会国际司共对9家企业(全部在香港上市)出具境外发行上市备 案补充材料要求，具体如下：华勤技术、欢创科技、锐明技术、瘦西湖、武汉聚芯、岚图汽车、麦科奥 特。 华勤技术 四、请说明发行人及下属公司经营范围涉及广告业务的情况，是否实际开展广告业务及具体运营情况。 五、请说明国信资本、青岛国投、青岛微电子的国资管序办理进展。 六、请说明本次拟参与"全流通"股东所持股份是否存在质押、冻结或其他权利瑕疵的情形。 请你公司补充说明以下事项，请律师核查并出具明确的法律意见： 一、请说明实际控制人支配的股东持有发行人的股份存在质押的具体情况，并结合偿债能力等情况说明 本次发行完成前后，股份质押情况是否可能导致控制权发生变化，是否构成《境内企业境外发行证券和 上市管理试行办法》第八条规定的境外发行上市禁止性情形。 二、请按照《监管规则适用指 ...

来源：瑞恩资本RyanbenCapital 中国企业赴香港上市，需要取得中国证监会的备案通知书。根据港交所上市规则，中国企业需在上市聆 讯审批日期至少4个营业日之前提交"备案通知书"。只有通过港交所的上市聆讯，企业才可以在港交所 挂牌上市。 本周(2025年11月10日至11月14日)中国证监会国际司共对10家企业(全部在香港上市)出具境外发行上市 备案补充材料要求，具体如下：微亿制造、融泰药业、华恒生物、魔视智能、望圆科技、晶晨半导体、 长春高新、英派药业、普源精电、艾米森。 微亿制造 请你公司补充说明以下事项，请律师核查并出具明确的法律意见： 一、请说明备案材料对控股股东认定结果不一致的原因及认定标准，并就控股股东的认定情况出具明确 结论性意见。 二、请说明国资管理程序办理进展。 三、请说明最近12个月内新增股东入股价格的合理性，该等入股价格之间存在差异的原因，是否存在利 益输送。 四、请按照《监管规则适用指引——境外发行上市类第2号：备案材料内容和格式指引》要求说明本次 发行上市方案，备案材料及招股说明书关于发行上市方案内容不一致的原因。 七、请说明发行人及下属公司经营范围涉及广告制作、发布、设计、代理 ...

Group 1 - The core viewpoint is that the China Securities Regulatory Commission (CSRC) aims to enhance the efficiency of overseas listing filings for companies by optimizing the cross-border connectivity mechanism [1] Group 2 - The announcement was made by CSRC Chairman Wu Qing during the 2025 Financial Street Forum [1]

Core Viewpoint - The article discusses the requirements and processes for Chinese companies to list overseas, particularly in Hong Kong, emphasizing the need for compliance with regulatory frameworks and the importance of legal opinions on various corporate actions [3][4][5]. Group 1: Regulatory Compliance - Chinese companies must obtain a filing notice from the China Securities Regulatory Commission (CSRC) before listing in Hong Kong, and this notice must be submitted at least four business days prior to the listing hearing [3]. - The CSRC has issued supplementary material requirements for five companies (four listed in Hong Kong and one in the U.S.) during the week of September 12 to September 18, 2025 [3]. Group 2: Corporate Structure and Valuation - Companies are required to clarify the compliance of their equity control structure, including foreign exchange management and tax regulations, and provide a detailed list of share price changes and valuation bases over the past 12 months [4][5]. - Legal opinions must be provided regarding the compliance of historical equity changes and the rationale behind share transfer pricing [5][6]. Group 3: Business Operations and Foreign Investment - Companies must explain whether their business activities fall under the negative list of foreign investment restrictions as per the 2024 version of the Special Management Measures for Foreign Investment Access [4][8]. - Specific details regarding the business models of companies providing healthcare solutions and internet services must be disclosed, including compliance with data protection regulations [9][11].